These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33526303)

  • 1. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
    Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
    J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry).
    McLaughlin V; Farber HW; Highland KB; Hemnes AR; Chakinala MM; Chin KM; Han M; Cho M; Tobore T; Rahman M; Kim NH
    J Heart Lung Transplant; 2024 Feb; 43(2):272-283. PubMed ID: 37778526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
    Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
    J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
    Koo R; Lo J; Bock MJ
    Cardiol Young; 2019 Jun; 29(6):849-851. PubMed ID: 31379316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
    Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
    Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
    Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
    Gaine S; Sitbon O; Channick RN; Chin KM; Sauter R; Galiè N; Hoeper MM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson V; Ghofrani HA; Lang I
    Chest; 2021 Jul; 160(1):277-286. PubMed ID: 33545163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
    Coghlan JG; Channick R; Chin K; Di Scala L; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Gaine S
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):37-47. PubMed ID: 29307087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selexipag: First Global Approval.
    Scott LJ
    Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
    Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
    Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
    Bruderer S; Hurst N; Remenova T; Dingemanse J
    Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selexipag: A Review in Pulmonary Arterial Hypertension.
    Duggan ST; Keam SJ; Burness CB
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):73-80. PubMed ID: 27988834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.
    Sitbon O; Chin KM; Channick RN; Benza RL; Di Scala L; Gaine S; Ghofrani HA; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson VF; Galiè N; Hoeper MM
    J Heart Lung Transplant; 2020 Apr; 39(4):300-309. PubMed ID: 32061506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension.
    Chang SA; Lee SH; Choi JH; Chung WJ; Choi JY; Kim HK; Jung HO; Park SM; Kim WJ; Jung SY; Chang HJ
    Expert Opin Drug Saf; 2022 Nov; 21(11):1423-1432. PubMed ID: 35451909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.